Unable to ‘align’ with FDA, Regeneron, Sanofi pull application for Libtayo in cervical cancer days before decision datenews2022-01-28T14:49:34+00:00January 28th, 2022|Fierce Pharma|
Fierce Pharma Asia—Samsung Biologics’ mRNA ambition, GSK COVID-19 vaccine supply; Fujifilm’s plant buynews2022-01-28T14:32:29+00:00January 28th, 2022|Fierce Pharma|
Eli Lilly, with Alzheimer’s top of mind, plots 300 jobs at new $445M manufacturing plantnews2022-01-28T13:59:38+00:00January 28th, 2022|Fierce Pharma|
UPDATED: Eli Lilly to plow a total of $1.5B into 2 new manufacturing plantsnews2022-01-28T13:59:38+00:00January 28th, 2022|Fierce Pharma|
Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headachenews2022-01-28T10:20:52+00:00January 28th, 2022|Fierce Pharma|
Biohaven keeps its foot on the gas for Nurtec-sponsored NASCAR, taps Sato as IndyCar drivernews2022-01-27T16:51:55+00:00January 27th, 2022|Fierce Pharma|
Pfizer in Texas showdown: Court hearing this week will decide if it can assist FDA in providing COVID documentsnews2022-01-27T15:20:05+00:00January 27th, 2022|Fierce Pharma|
FDA slaps Aurobindo with warning letter on API testing failures, repeated violationsnews2022-01-27T13:36:08+00:00January 27th, 2022|Fierce Pharma|
Novo Nordisk’s Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analystsnews2022-01-27T13:24:34+00:00January 27th, 2022|Fierce Pharma|
What competition? Vertex touts Trikafta’s competitive edge on back of strong 2021news2022-01-27T12:09:31+00:00January 27th, 2022|Fierce Pharma|
